Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity.
Typically, screening collections of pharmaceutical companies contain more than a million compounds today. However, for certain high-throughput screening (HTS) campaigns, constraints posed by the assay throughput and/or the reagent costs make it impractical to screen the entire deck. Therefore, it is desirable to effectively screen subsets of the collection based on a hypothesis or a diversity selection. How to select compound subsets is a subject of ongoing debate. The authors present an approach based on extended connectivity fingerprints to carry out diversity selection on a per plate basis (instead of a per compound basis). HTS data from 35 Novartis screens spanning 5 target classes were investigated to assess the performance of this approach. The analysis shows that selecting a fingerprint-diverse subset of 250K compounds, representing 20% of the screening deck, would have achieved significantly higher hit rates for 86% of the screens. This measure also outperforms the Murcko scaffold-based plate selection described previously, where only 49% of the screens showed similar improvements. Strikingly, the 2-fold improvement in average hit rates observed for 3 of 5 target classes in the data set indicates a target bias of the plate (and thus compound) selection method. Even though the diverse subset selection lacks any target hypothesis, its application shows significantly better results for some targets-namely, G-protein-coupled receptors, proteases, and protein-protein interactions-but not for kinase and pathway screens. The synthetic origin of the compounds in the diverse subset appears to influence the screening hit rates. Natural products were the most diverse compound class, with significantly higher hit rates compared to the compounds from the traditional synthetic and combinatorial libraries. These results offer empirical guidelines for plate-based diversity selection to enhance hit rates, based on target class and the library type being screened.
Sukuru
Sai Chetan K
SC
Lead Discovery Informatics, Center for Proteomic Chemistry Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.
Jenkins
Jeremy L
JL
Beckwith
Rohan E J
RE
Scheiber
Josef
J
Bender
Andreas
A
Mikhailov
Dmitri
D
Davies
John W
JW
Glick
Meir
M
D020650:Combinatorial Chemistry Techniques / Q000295:instrumentation*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004364:Pharmaceutical Preparations / Q000032:analysis* / Q000737:chemistry*
D004364:Pharmaceutical Preparations